Journal Article

TERT Promoter Mutations Frequency Across Race, Sex, and Cancer Type

Machaalani, Marc, Choueiri, Toni K, Pomerantz, Mark, Nassar, Amin H, Xie, Wanling, Nawfal, Rashad, El Zarif, Talal

2024

Overview

Background Telomerase reverse transcriptase (TERT) gene promoter mutations have been explored, as biomarkers of improved survival for patients with cancer receiving immune checkpoint inhibitors. We sought to investigate their prevalence by race and sex across different cancer types to inform patient selection in clinical trials. Results In this observational study, 31 925 patients with cancer underwent next-generation sequencing of their tumors with 88% (27 970) patients self-reported being Whites, 7.1% (2273) Asians, and 5.3% (1682) Blacks. Examining the distribution of TERT promoter mutations by race, White patients with melanoma harbored more TERT promoter mutations than Asian and Black patients (OR = 25.83; 95%CI, 6.84-217.42; P < .001). In contrast, Asian patients with head and neck cancer (HNC) harbored more TERT promoter mutations compared to White patients (OR = 2.47; 95%CI, 1.39-4.37; P = .004). In addition, the distribution of TERT promoter mutations differed by sex. Males were enriched for TERT gene promoter mutations compared to females with melanoma (OR = 1.82; 95%CI, 1.53-2.16; P < .001), cancer of unknown primary (OR = 1.96; 95%CI, 1.43-2.69; P < .001), hepatobiliary (OR = 3.89; 95%CI, 2.65-5.69; P < .001), and thyroid cancers (OR = 1.42; 95%CI, 1.10-1.84; P = .0087), while females were more enriched for TERT promoter mutations compared to males for HNC (OR = 0.56; 95%CI, 0.39-0.81; P = .0021). Conclusions The prevalence of TERT gene promoter mutations varies among patients with cancer based on race and sex. These findings inform our understanding of cancer biology and can assist in the design of future clinical trials that leverage drugs targeting TERT promoter dependencies. TERT gene promoter mutations have been explored as biomarkers of improved survival for patients with cancer receiving immune checkpoint inhibitors. This article reports their prevalence by race and sex across different cancer types to inform patient selection in clinical trials.

• Publisher: Oxford University Press
• Subject: Analysis / Cancer / Clinical trials / Diagnosis / Female / Head and Neck Neoplasms - genetics / Health aspects / Health disparities / Humans / Male / Melanoma / Melanoma - genetics / Mutation / Physiological aspects / Promoter Regions, Genetic - genetics / Promoters (Genetics) / Telomerase / Telomerase - genetics / Thyroid Neoplasms - pathology